Home » XOMA LICENSES BCE TECHNOLOGY FOR RECOMBINANT PROTEIN PRODUCTION TO WYETH
XOMA LICENSES BCE TECHNOLOGY FOR RECOMBINANT PROTEIN PRODUCTION TO WYETH
XOMA Ltd. (Nasdaq:XOMA) today announced that it has granted Wyeth (NYSE:WYE) a non-exclusive, worldwide license for XOMA's expression technology. Under the agreement, Wyeth receives a license to use XOMA's technology for the development and production of recombinant proteins. Details of the initial payment and future contingent payments to XOMA were not disclosed.
Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1048426XSL_NEWSML_TO_NEWSML_WEB.xml)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May